ReviewInternational journal of nephrology and renovascular disease2020
Erythropoietin Resistance in Patients with Chronic Kidney Disease: Current Perspectives.
Review in International journal of nephrology and renovascular disease, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 48 citations in OpenAlex.
- Dapagliflozin improves hemoglobin and anemia in chronic kidney disease: a systematic review and meta-analysis.Renal failure · 2026Pooled it
- Association of Serum 1,25-Dihydroxyvitamin D Levels with Erythropoietin Resistance Index-Based Relative Erythropoiesis-Stimulating Agent Hyporesponsiveness in Pre-Dialysis Chronic Kidney Disease.International journal of molecular sciences · 2026Article
- Relationships of high mean corpuscular volume, low total iron binding capacity and protein-energy wasting in patients on maintenance hemodialysis.Clinical and experimental nephrology · 2026Article
- Ascorbic acid as an adjunct therapy for anemia in erythropoietin-treated hemodialysis patients: a systematic review and meta-analysis.Clinical kidney journal · 2026Article
- Association of Malnutrition, Inflammation, and Residual Kidney Clearance in Peritoneal Dialysis: A Cross-Sectional Analysis.International journal of nephrology · 2026Article
- Current research on the HIF-2α-EPO-Hb axis in hypoxic environments: from molecular mechanisms to clinical.Frontiers in medicine · 2026Review
- Duration, dose, and responsiveness to erythropoiesis-stimulating agents and risk of osteoporotic fracture among patients with chronic kidney disease in Hong Kong: a nested case-control study.EClinicalMedicine · 2025Article
- Comment on: Erythropoietin resistance among pediatric patients on chronic hemodialysis: A cross-sectional study.Pediatric nephrology (Berlin, Germany) · 2025Article
- Article
- A European Delphi study on the management of anaemia of CKD: unmet needs in personalized treatment.Journal of nephrology · 2025Article
- Engineering Marrow-Mimetic Hydrogel Platforms Enhance Erythropoiesis: A Mechanobiology-Driven Approach for Transfusion Red Blood Cell Production.Gels (Basel, Switzerland) · 2025Article
- Ras Guanine Nucleotide-Releasing Protein-4 Inhibits Erythropoietin Production in Diabetic Mice with Kidney Disease by Degrading HIF2A.Diabetes & metabolism journal · 2025Article
- Ziltivekimab for anemia and atherosclerosis in chronic kidney disease: a new hope?Journal of nephrology · 2025Review
- Impact of Iron Deficiency and Erythropoiesis-Stimulating Agents on Anemia in CKD Progression.International journal of nephrology · 2025Article
- Therapeutic potential of L-Carnitine in improving adenine-induced hematological abnormalities in rats: A preclinical pharmacological study.Open veterinary journal · 2025Article
- Progress in the application of novel inflammatory indicators in chronic kidney disease.Frontiers in medicine · 2025Review
- Article
- Article
- Evaluation of hepcidin-25/erythroferrone ratio as a potential biomarker for iron utility and erythropoiesis responsiveness to erythropoiesis-stimulating therapy in comparison to immature erythrocyte/reticulocyte parameters in hemodialysis patients.Hematology, transfusion and cell therapy · 2024Article
- Short-term effect of low-dose roxadustat combined with erythropoiesis-stimulating agent treatment for erythropoietin-resistant anemia in patients undergoing maintenance hemodialysis.Frontiers in endocrinology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anemia is a frequent complication of chronic kidney disease, and its primary cause is erythropoietin deficiency. After diagnosis, treatment begins with administration of an erythropoiesis-stimulating agent (ESA). However, some patients present with resistance to ESA, which needs to be reversed, as it can increase the risk of death in patients with kidney disease. Therefore, we provide a discussion of the current literature regarding the factors that can modify the response to this class of drugs and the strategies that can be considered to optimize the benefits of treating anemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.